CONTEXT: Animal models suggest that the osteoblast-stimulating actions of PTH are mediated by acute suppression of sclerostin, an inhibitor of the anabolic Wnt pathway. The immediate physiological changes in serum sclerostin in response to PTH infusion have not been reported in human studies. OBJECTIVE: We sought to determine the acute physiological effects of PTH infusion on serum sclerostin and bone turnover markers in healthy adult men. DESIGN, SETTING, AND PARTICIPANTS: Fifty-three healthy adult men underwent an 18-h iv infusion of human PTH(1-34) at a dose of 0.55 U/kg · h. OUTCOMES: Serum levels of ionized calcium, sclerostin, and markers of bone formation (osteocalcin and amino-terminal propeptide of type I procollagen) and bone resorption (C-telopeptide and N-telopeptide) were obtained at 0, 6, 12, and 18 h. RESULTS: Serum ionized calcium, C-telopeptide, and N-telopeptide increased, and osteocalcin and amino-terminal propeptide of type I procollagen fell linearly throughout the PTH infusion (P < 0.001 for all). Average ± sem sclerostin levels declined from 936 ± 65 to 813 ± 63 pg/ml at 6 h (P < 0.001) and remained stably suppressed for the duration of the PTH infusion. There were no significant correlations between change in sclerostin and change in bone markers. CONCLUSIONS: Serum sclerostin declined in response to acute PTH infusion within 6 h in healthy adult men. The early plateau in sclerostin suppression may indicate that maximal stimulation of the Wnt pathway is achieved quickly after exposure to PTH. Our findings support the hypothesis that PTH may mediate its anabolic effects in part via suppression of sclerostin.
CONTEXT: Animal models suggest that the osteoblast-stimulating actions of PTH are mediated by acute suppression of sclerostin, an inhibitor of the anabolic Wnt pathway. The immediate physiological changes in serum sclerostin in response to PTH infusion have not been reported in human studies. OBJECTIVE: We sought to determine the acute physiological effects of PTH infusion on serum sclerostin and bone turnover markers in healthy adult men. DESIGN, SETTING, AND PARTICIPANTS: Fifty-three healthy adult men underwent an 18-h iv infusion of humanPTH(1-34) at a dose of 0.55 U/kg · h. OUTCOMES: Serum levels of ionized calcium, sclerostin, and markers of bone formation (osteocalcin and amino-terminal propeptide of type I procollagen) and bone resorption (C-telopeptide and N-telopeptide) were obtained at 0, 6, 12, and 18 h. RESULTS: Serum ionized calcium, C-telopeptide, and N-telopeptide increased, and osteocalcin and amino-terminal propeptide of type I procollagen fell linearly throughout the PTH infusion (P < 0.001 for all). Average ± sem sclerostin levels declined from 936 ± 65 to 813 ± 63 pg/ml at 6 h (P < 0.001) and remained stably suppressed for the duration of the PTH infusion. There were no significant correlations between change in sclerostin and change in bone markers. CONCLUSIONS: Serum sclerostin declined in response to acute PTH infusion within 6 h in healthy adult men. The early plateau in sclerostin suppression may indicate that maximal stimulation of the Wnt pathway is achieved quickly after exposure to PTH. Our findings support the hypothesis that PTH may mediate its anabolic effects in part via suppression of sclerostin.
Authors: Gabriela G Loots; Michaela Kneissel; Hansjoerg Keller; Myma Baptist; Jessie Chang; Nicole M Collette; Dmitriy Ovcharenko; Ingrid Plajzer-Frick; Edward M Rubin Journal: Genome Res Date: 2005-06-17 Impact factor: 9.043
Authors: Olivier Leupin; Ina Kramer; Nicole M Collette; Gabriela G Loots; François Natt; Michaela Kneissel; Hansjoerg Keller Journal: J Bone Miner Res Date: 2007-12 Impact factor: 6.741
Authors: T Bellido; A A Ali; I Gubrij; L I Plotkin; Q Fu; C A O'Brien; S C Manolagas; R L Jilka Journal: Endocrinology Date: 2005-08-04 Impact factor: 4.736
Authors: C Joborn; S Ljunghall; K Larsson; E Lindh; T Naessén; L Wide; G Akerström; J Rastad Journal: Clin Endocrinol (Oxf) Date: 1991-05 Impact factor: 3.478
Authors: Hang Lee; Joel S Finkelstein; Megan Miller; Sarah J Comeaux; Rachel I Cohen; Benjamin Z Leder Journal: J Clin Endocrinol Metab Date: 2005-12-13 Impact factor: 5.958
Authors: S J Silverberg; E Shane; L de la Cruz; D W Dempster; F Feldman; D Seldin; T P Jacobs; E S Siris; M Cafferty; M V Parisien Journal: J Bone Miner Res Date: 1989-06 Impact factor: 6.741
Authors: G Silvestrini; P Ballanti; M Leopizzi; M Sebastiani; S Berni; M Di Vito; E Bonucci Journal: J Mol Histol Date: 2007-06-05 Impact factor: 2.611
Authors: Charles A O'Brien; Lilian I Plotkin; Carlo Galli; Joseph J Goellner; Arancha R Gortazar; Matthew R Allen; Alexander G Robling; Mary Bouxsein; Ernestina Schipani; Charles H Turner; Robert L Jilka; Robert S Weinstein; Stavros C Manolagas; Teresita Bellido Journal: PLoS One Date: 2008-08-13 Impact factor: 3.240
Authors: Alexander T Faje; Pouneh K Fazeli; Debra K Katzman; Karen K Miller; Anne Breggia; Clifford J Rosen; Nara Mendes; Anne Klibanski; Madhusmita Misra Journal: Bone Date: 2012-06-15 Impact factor: 4.398
Authors: Joy N Tsai; Yuli Zhu; Katelyn Foley; Hang Lee; Sherri-Ann Burnett-Bowie; Robert M Neer; Benjamin Z Leder Journal: J Clin Endocrinol Metab Date: 2015-05-01 Impact factor: 5.958
Authors: J M Spatz; E E Fields; E W Yu; P Divieti Pajevic; M L Bouxsein; J D Sibonga; S R Zwart; S M Smith Journal: J Clin Endocrinol Metab Date: 2012-07-05 Impact factor: 5.958
Authors: Sandra Jastrzebski; Judith Kalinowski; Marina Stolina; Faryal Mirza; Elena Torreggiani; Ivo Kalajzic; Hee Yeon Won; Sun-Kyeong Lee; Joseph Lorenzo Journal: J Bone Miner Res Date: 2013-03 Impact factor: 6.741